Reuters logo
9 个月前
BRIEF-Agenus to start the phase 1/2 clinical trial of anti-OX40
2016年11月30日 / 下午2点27分 / 9 个月前

BRIEF-Agenus to start the phase 1/2 clinical trial of anti-OX40

Nov 30 (Reuters) - Agenus Inc :

* Agenus announces commencement of phase 1/2 clinical trial of anti-OX40 checkpoint antibody INCAGN1949 in patients with solid tumors

* Agenus Inc - trial is being conducted by, and in collaboration with, Incyte Corporation.

* Agenus Inc - third antibody from Agenus to enter clinic this year

* Agenus Inc - part 2 of trial is planned to evaluate recommended dose of INCAGN1949 in multiple tumor types

* Agenus-Open-Label, dose-escalation portion of trial will evaluate safety, tolerability of INCAGN1949 in patients with advanced/metastatic solid tumors Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below